FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2779202387> ?p ?o ?g. }

• W2779202387 abstract "Background Breast cancer is highly prevalent in older women. Although surgery is the main initial treatment for younger population, research has demonstrated that older women with primary breast cancer have different tumour biology, comorbidities, and patient preferences from younger patients, and hence may benefit from primary endocrine therapy (PETx), such as Tamoxifen and aromatase inhibitors (AIs). However, there is no cost-effectiveness study that compares the use of different treatment strategies in older women. Aim of studyThis study aimed to evaluate the clinical and cost-effectiveness of using PETx against surgery as the initial treatment strategy in older women with primary breast cancer. MethodsThis research included four stages. First, a retrospective cohort study was conducted to describe the treatment pathways, and evaluate the effectiveness and costs associated with using different treatment strategies by using a longitudinal database of 1,759 older women, who were diagnosed with primary breast cancer at ages over 70 years old in breast cancer units in Nottingham. Regression analyses, including survival analysis and generalised linear model, were used to identify the covariates, the predict death rates and costs, respectively.Second, a systematic review of economic evaluation studies was conducted using NHS Economic Evaluation Database, Cochrane Library, Ovid Medline, PubMed, and EMBASE to identify full economic evaluations that compared different treatment strategies in postmenopausal women with primary breast cancer. Quality and modelling methodologies of the included studies were assessed and summarised.Finally, a Markov model was conducted from the systematic review to estimate the lifetime costs and quality adjusted life year (QALYs) associated with the use of PETx as against surgery in a hypothetical cohort of older women with primary breast cancer and ER-positive status. The analysis took the UK NHS perspective with a lifetime horizon. Transition probabilities were estimated using parametric survival models derived from the longitudinal database. Resource use and costs were assessed in British pounds of the year 2014 using the longitudinal database. Utilities were derived from literature, including Prescott et al. (2007) (1), Fallowfield et al. (1994), and Peasgood et al. (2010)(2). Both costs and outcomes were discounted by 3.5% annually. A subgroup analysis was conducted for patients with higher oestrogen receptor content (H-score >250 out of 300). PSA was conducted and aggregated results were presented in cost-effectiveness plane and cost-effectiveness acceptability curve. Sensitivity analysis was also conducted to investigate the impact of uncertain parameters and model assumptions.ResultsRetrospective analysis of the cohort study found that most patients received surgery (n=350; 52.08%) or PETx (n=322; 47.92%) as the initial treatment strategy. The most common adjuvant therapy was endocrine therapy (n=164; 46.86%). Comparing to those received surgery as an initial treatment, patients who received PETx had a significantly higher adjusted risk of breast cancer-related death (HR: 2.15; 95%CI: 1.03, 4.46), and lower costs (mean difference: -£3558.87; 95%CI: -£4018.11, -£3105.39). Overall, 29 economic evaluations were included from the systematic reviews and studies that assessed surgery and none assessed PETx as the initial treatment. Most of the included economic studies used a Markov model with lifetime horizon and one-year cycle length. Nine studies which included subgroup analysis for older women (over 65 years old) used similar economic models and transition states to those that were used for younger women (50 to 65 years old) with primary breast cancer. The key disease-related health states were disease-free, recurrence, and death. Recurrence was mostly separated into locoregional and distant recurrence. These findings were used to design a Markov model in the following decision modelling. In the base-case analysis of decision analytical modelling, the deterministic results showed that patients who received PETx as the initial treatment had lower costs and QALYs compared with patients who received surgery; the mean ICUR was £194 per QALY. However, for patients with H-score >250, PETx was associated with higher costs and lower QALYs; the mean ICUR was -£1849 per QALY.In the probabilistic sensitivity analysis, PETx was associated with lower costs and QALYs. The mean ICUR was £363 per QALY, 95%CI: -6014.99, 5,756.86). However, for patients with H-score >250, PETx was associated with higher costs and lower QALYs. The mean ICUR was -£390.67 per QALY (95%CI: -7,295, 7776.54). The probability of PETx being cost-effective in a situation where the decision-maker is willing to accept (WTA) £21,000 per QALY was 24%. In the subgroup analysis, PETx was associated with slightly lower QALYs and higher costs. The probability of PETx being cost-effective in a situation where the decision-maker is willing to accept £21,000 per QALY was 43%.ConclusionThe main findings from this study showed that PETx was not cost-effective compared to surgery. However, this study was mainly based on the effectiveness and cost from a single observational study in a secondary care setting, and other information (evidence) that may bias the effectiveness and cost estimates, including frailty status, adherence, comorbidities, and other unmeasured confounders were not recorded, and thus, may bias the cost-effectiveness results. Future research is recommended to collect further information on patients’ characteristics, including frailty, adherence, and adverse events that may influence the cost-effectiveness results. Moreover, collecting detailed estimation of the resource use in order to provide an accurate estimate for costs." @default.
• W2779202387 created "2018-01-05" @default.
• W2779202387 creator A5036961529 @default.
• W2779202387 date "2017-12-14" @default.
• W2779202387 modified "2023-09-27" @default.
• W2779202387 title "Cost-effectiveness of primary endocrine therapy comparing against surgery as the initial treatment strategy in older women with primary breast cancer" @default.
• W2779202387 hasPublicationYear "2017" @default.
• W2779202387 type Work @default.
• W2779202387 sameAs 2779202387 @default.
• W2779202387 citedByCount "0" @default.
• W2779202387 crossrefType "dissertation" @default.
• W2779202387 hasAuthorship W2779202387A5036961529 @default.
• W2779202387 hasConcept C112930515 @default.
• W2779202387 hasConcept C121608353 @default.
• W2779202387 hasConcept C126322002 @default.
• W2779202387 hasConcept C143998085 @default.
• W2779202387 hasConcept C159110408 @default.
• W2779202387 hasConcept C167135981 @default.
• W2779202387 hasConcept C17744445 @default.
• W2779202387 hasConcept C199539241 @default.
• W2779202387 hasConcept C201903717 @default.
• W2779202387 hasConcept C2776478404 @default.
• W2779202387 hasConcept C2777176818 @default.
• W2779202387 hasConcept C2779473830 @default.
• W2779202387 hasConcept C2779951463 @default.
• W2779202387 hasConcept C2908647359 @default.
• W2779202387 hasConcept C29456083 @default.
• W2779202387 hasConcept C3019080777 @default.
• W2779202387 hasConcept C530470458 @default.
• W2779202387 hasConcept C71924100 @default.
• W2779202387 hasConcept C95190672 @default.
• W2779202387 hasConcept C99454951 @default.
• W2779202387 hasConceptScore W2779202387C112930515 @default.
• W2779202387 hasConceptScore W2779202387C121608353 @default.
• W2779202387 hasConceptScore W2779202387C126322002 @default.
• W2779202387 hasConceptScore W2779202387C143998085 @default.
• W2779202387 hasConceptScore W2779202387C159110408 @default.
• W2779202387 hasConceptScore W2779202387C167135981 @default.
• W2779202387 hasConceptScore W2779202387C17744445 @default.
• W2779202387 hasConceptScore W2779202387C199539241 @default.
• W2779202387 hasConceptScore W2779202387C201903717 @default.
• W2779202387 hasConceptScore W2779202387C2776478404 @default.
• W2779202387 hasConceptScore W2779202387C2777176818 @default.
• W2779202387 hasConceptScore W2779202387C2779473830 @default.
• W2779202387 hasConceptScore W2779202387C2779951463 @default.
• W2779202387 hasConceptScore W2779202387C2908647359 @default.
• W2779202387 hasConceptScore W2779202387C29456083 @default.
• W2779202387 hasConceptScore W2779202387C3019080777 @default.
• W2779202387 hasConceptScore W2779202387C530470458 @default.
• W2779202387 hasConceptScore W2779202387C71924100 @default.
• W2779202387 hasConceptScore W2779202387C95190672 @default.
• W2779202387 hasConceptScore W2779202387C99454951 @default.
• W2779202387 hasLocation W27792023871 @default.
• W2779202387 hasOpenAccess W2779202387 @default.
• W2779202387 hasPrimaryLocation W27792023871 @default.
• W2779202387 hasRelatedWork W2024910720 @default.
• W2779202387 hasRelatedWork W2034498175 @default.
• W2779202387 hasRelatedWork W2056774794 @default.
• W2779202387 hasRelatedWork W2149640871 @default.
• W2779202387 hasRelatedWork W2194721905 @default.
• W2779202387 hasRelatedWork W2556443239 @default.
• W2779202387 hasRelatedWork W2557286867 @default.
• W2779202387 hasRelatedWork W2560749444 @default.
• W2779202387 hasRelatedWork W2594817066 @default.
• W2779202387 hasRelatedWork W2883673786 @default.
• W2779202387 hasRelatedWork W2900294285 @default.
• W2779202387 hasRelatedWork W2906542507 @default.
• W2779202387 hasRelatedWork W2909733677 @default.
• W2779202387 hasRelatedWork W2979550581 @default.
• W2779202387 hasRelatedWork W2990279566 @default.
• W2779202387 hasRelatedWork W3003898668 @default.
• W2779202387 hasRelatedWork W3109511009 @default.
• W2779202387 hasRelatedWork W3153375368 @default.
• W2779202387 hasRelatedWork W3171191497 @default.
• W2779202387 hasRelatedWork W3194653434 @default.
• W2779202387 isParatext "false" @default.
• W2779202387 isRetracted "false" @default.
• W2779202387 magId "2779202387" @default.
• W2779202387 workType "dissertation" @default.